Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Goldman Sachs Physical Gold ETF (AAAU) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance

Goldman Sachs Physical Gold ETF
Amphastar Pharmaceuticals Inc

Price performance

Price movement over the last 24 hours

Key statistics

Goldman Sachs Physical Gold ETF vs Amphastar Pharmaceuticals Inc — how do they compare? Goldman Sachs Physical Gold ETF trades at $40.11, while Amphastar Pharmaceuticals Inc trades at $18.77 (market cap $885.83M). The key difference: Goldman Sachs Physical Gold ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

AAAUAMPH
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$53.21$30.81
52-Week Low
$32.29$16.87
Market Cap
$885.83M
Enterprise Value
$1.28B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Goldman Sachs Physical Gold ETF

AAAU, a US-listed gold-focused investment vehicle, trades at $41.04 with a 1.01% daily gain. Technical indicators show a bearish bias with moving averages signaling selling pressure, while oscillators remain neutral. The stock faces resistance at $41 with support at $40. Recent gold market dynamics show central bank accumulation and analyst price targets ranging from $4,500-$5,500 per ounce for the underlying commodity.

Gold's structural tailwinds from central bank demand and inflation hedging support long-term upside, though near-term headwinds include Fed policy uncertainty and dollar strength. The stock offers exposure to gold's safe-haven appeal but remains vulnerable to interest rate volatility and technical resistance levels.

Amphastar Pharmaceuticals Inc

AMPH trades at $19.61, down 0.15% with a bearish technical outlook. The stock shows mixed fundamentals with a P/E of 11.81 and net margin of 11%, but recent earnings misses and declining 2026 profit projections raise concerns. Recent news includes a Zacks Strong Sell rating and a securities law investigation, while management focuses on transitioning to proprietary drugs for growth.

The outlook remains cautious with analyst consensus at Hold (66.7%) and a $20.40 price target offering limited upside. Key risks include earnings volatility, competitive pressures, and legal scrutiny. The stock presents moderate value but requires careful monitoring of execution on growth initiatives and upcoming Q2 earnings.

Returns comparison

Trailing returns across standard periods

About Goldman Sachs Physical Gold ETF

AAAU tracks the price of gold bullion by holding physical gold bars in secure vaults. Managed by Goldman Sachs, this ETF offers a cost-effective way to gain direct exposure to gold without the logistical challenges of storage or insurance.

Read more on AAAU

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH